Cerecor Announces Clearance of IND for FP01
(firmenpresse) - BALTIMORE, MD -- (Marketwire) -- 04/11/12 -- , a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration (FDA). The Company plans to immediately characterize the pharmacokinetics of in humans and thereafter to initiate an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI).
"Acceptance by the FDA of this application and the advancement of FP01 to clinical testing are important milestones for the Company and key steps along the path to commercialize a treatment for acute and chronic cough. The data we plan to generate from the initial Phase II study will educate us about the effect size of FP01 as an antitussive, providing for future studies," said Dr. Blake Paterson, CEO and co-founder of Cerecor.
About Cerecor Inc.
Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's also includes preclinical drug development candidates in .
For More Information, contact:
John Dierkes
Kennedy Advisors
(410) 935-9334
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.04.2012 - 15:40 Uhr
Sprache: Deutsch
News-ID 134003
Anzahl Zeichen: 0
contact information:
Town:
BALTIMORE, MD
Kategorie:
Drugs
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cerecor Announces Clearance of IND for FP01"
steht unter der journalistisch-redaktionellen Verantwortung von
Cerecor Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
